Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Trump's recent announcement that he's procured $7 trillion in incoming investments to the U.S. may very well have been an underestimate.

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the plate with a major plan to grow its U.S. footprint. | As concerns around ...

The Swiss pharmaceutical giant plans to build seven new facilities and expand others in an effort that will allow it to ...

Novartis (NVS) plans to invest $23B in U.S. facilities over the next five years, creating 13K+ jobs amid tariff threats. Read ...

Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part of ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Swiss pharmaceutical giant Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities, ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...